Freeform Search

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: l2 and l1

Display: 10 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search Clear Interrupt

Search History

DATE: Monday, March 01, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L5	l2 and l1	41	L5
L4	l2 same l1	0	L4
L3	L2 with l1	0	L3
L2	deletion or knock-out	100436	L2
L1	transgenic with (AFP or alpha-Fetoprotein)	59	L1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 18:19:01 ON 01 MAR 2004)

FILE 'MEDLINE, CANCERLIT, BIOTECHDS, EMBASE, BIOSIS' ENTERED AT 18:19:28
ON 01 MAR 2004

L1	43272	S	ALPHA-FETOPROTEIN OR AFP
L2	165535	S	TRANSGENIC
L3	8138	S	KNOCK-OUT
L4	172186	S	L3 OR L2
L5	315	S	L4 AND L1
L6	71542	S	NULL OR KNOCK-OUT
L7	4	S	L6 AND L5
L8	1		DUP REM L7 (3 DUPLICATES REMOVED)
L9	304373	S	DELETED OR DELETION
L10	17	S	L9 AND L5
L11	6		DUP REM L10 (11 DUPLICATES REMOVED)

> d bib ab 1-6

L11 ANSWER 1 OF 6 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 2001-07102 BIOTECHDS
TI New non-human genetically modified mammal lacking the **alpha-fetoprotein**, useful for studying, testing or screening of anti-osteoporosis fertilization and/or contraceptive methods, compound and compositions;
non-human **transgenic** mammal useful for drug screening
AU Gabant P; Roscam-Szpirer J
PA Univ.Brussels-Free
LO Brussels, Belgium.
PI WO 2001003501 18 Jan 2001
AI WO 2000-BE81 11 Jul 2000
PRAI US 1999-143269 12 Jul 1999
DT Patent
LA English
OS WPI: 2001-159325 [16]
AB A non-human genetically modified mammal is claimed. It contains a mutation, a partial or total **deletion** in the genetic sequence encoding the wild-type mammal **alpha-fetoprotein** (**AFP**). Also claimed are: a pluripotent embryonic stem cell, preferably a mouse cell containing a partial or total **deletion** of a genetic sequence encoding a mammal **AFP**, and a study, testing or screening method and device of known or unknown molecules that are able to fix the **AFP** or its portion and that may be used as agonist or antagonists of esterogens, for fertilization or contraceptive methods and compositions or for the preventing or treating osteoporosis. The non-human mammal is useful for studying, testing or screening of anti-osteoporosis fertilization or contraceptive methods, compounds and compositions. The molecules discovered by the screening method that are able to fix the **AFP** or its portion may be used as agonist or antagonist of esterogens, for fertilization or contraceptive methods and compositions or for preventing or treating osteoporosis.

L11 ANSWER 6 OF 6 MEDLINE on STN DUPLICATE 5
AN 90216885 MEDLINE
DN PubMed ID: 1691194
TI The ontogeny of **alpha-fetoprotein** gene expression in the mouse gastrointestinal tract.
AU Tyner A L; Godbout R; Compton R S; Tilghman S M
CS Howard Hughes Medical Institute, Princeton University, New Jersey 08544.
NC CA44976 (NCI)
SO Journal of cell biology, (1990 Apr) 110 (4) 915-27.
Journal code: 0375356. ISSN: 0021-9525.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199005
ED Entered STN: 19900622
Last Updated on STN: 19960129
Entered Medline: 19900511
AB The ontogeny of **alpha-fetoprotein** (**AFP**) gene expression has been examined in the fetal and adult mouse gastrointestinal tract. **AFP** mRNA constitutes approximately 0.1% of total mRNA in the fetal gut. The transcripts were localized by in situ hybridization to the epithelial cells lining the villi of the fetal gut. At birth, **AFP** mRNA declines rapidly to achieve low adult basal levels, which are not affected by different alleles of raf, a gene that determines the adult basal level of **AFP** mRNA in the liver. The basal level in the adult gut is the consequence of continued **AFP** transcription in a small number of enteroendocrine cells that are distributed infrequently on the villi. These cells were identified by double antibody staining with antibodies to chromogranin A, an enteroendocrine cell marker and **AFP**. Previous studies resulted in the generation of a line of **transgenic** mice containing an internally **deleted** **AFP** gene that was greatly overexpressed in the fetal gut. The basis for the inappropriately high level expression of the transgene was shown to be the consequence of very high levels of transcription in the epithelial cells of the villi rather than to expression in inappropriate cell types. The cis-acting DNA sequences required for expression of the **AFP** gene in the gut were investigated using Caco-2 cells, a human colon adenocarcinoma cell line. These experiments indicated that, with one exception, the regulatory elements required in both the promoter and enhancer regions of the gene coincided with those that are necessary for high level expression in the liver. The one exception was enhancer II, located 5 kbp of DNA upstream of the gene, which exhibited no activity in Caco-2 cells.

L11 ANSWER 5 OF 6 MEDLINE on STN DUPLICATE 4
AN 95246916 MEDLINE
DN PubMed ID: 7537233
TI Developmental regulation of **alpha-fetoprotein** expression in intestinal epithelial cells of **transgenic** mice.
AU Cirillo L A; Emerson J A; Vacher J; Tyner A L
CS Department of Biology, Carleton College, Northfield, Minnesota 55057, USA.
NC CA44976 (NCI)
SO Developmental biology, (1995 Apr) 168 (2) 395-405.
Journal code: 0372762. ISSN: 0012-1606.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199505
ED Entered STN: 19950608
Last Updated on STN: 19960129
Entered Medline: 19950526
AB The **alpha-fetoprotein** (**AFP**) gene is transcribed in most epithelial cells lining the fetal mouse small intestine, but transcription persists in only a subset of enteroendocrine cells representing less than 1% of the total intestinal epithelial cells in the adult. The decrease in **AFP** expression after birth is mediated in part by a repressor element lying between -838 and -250 bp of the **AFP** gene. **Deletion** of this element from **AFP** minigene constructs results in high-level minigene expression in the intestines of adult **transgenic** mice. Although high levels of **AFP** minigene RNA are expressed, the fetal pattern of expression is not maintained upon **deletion** of the repressor element. Instead, the number of cells in which the minigene is expressed increases from less than 1% to approximately 10% of the epithelial cells in the adult small intestine, and includes the majority of the goblet cells in addition to the enteroendocrine cells. In contrast, the pattern of **AFP** minigene expression in the enterocytes is unaffected by **deletion** of the repressor element and continues to decrease in the neonate. These studies indicate that the identified **AFP** repressor is active specifically in goblet cells. The decrease in **AFP** expression in the enterocytes may be mediated by a separate cis-acting element that is contained in the **AFP** minigene construct. Alternatively, it is possible that mature enterocytes lack some of the positive factors required for initiation and maintenance of minigene transcription in the absence of the identified negative element.

PALM INTRANET

Day : Monday
Date: 3/1/2004
Time: 16:12:47

Inventor Name Search Result

Your Search was:

Last Name = GABANT
First Name = PHILIPPE

Application#	Patent#	Status	Date Filed	Title	Inventor Name 9
60494021	Not Issued	019	01/01/0001	LOCALISATION, IDENTIFICATION AND TRACKING OF BIOLOGICAL SAMPLES USING ELECTRONIC TAGGING	GABANT, PHILIPPE
60143269	Not Issued	159	07/12/1999	NON-HUMAN GENETICALLY MODIFIED MAMMAL LACKING THE ALPHA-FETOPROTEIN	GABANT , PHILIPPE
10468536	Not Issued	020	01/23/2004	METHOD FOR THE SELECTION OF RECOMBINATION CLONES COMPRISING A SEQUENCE ENCODING AN ANTIDOTE PROTEIN TO A TOXIC MOLECULE	GABANT, PHILIPPE
10168774	Not Issued	030	06/20/2002	DOUBLE SELECTION VECTOR	GABANT, PHILIPPE
10031021	Not Issued	071	03/19/2002	NON-HUMAN GENETICALLY MODIFIED MAMMAL LACKING THE ALPHA-FETOPROTEIN	GABANT, PHILIPPE
10030785	Not Issued	019	01/01/0001	NON-HUMAN GENETICALLY MODIFIED MAMMAL LACKING THE ALPHA-FETOPROTEIN	GABANT, PHILIPPE
09634039	Not Issued	061	08/08/2000	CLONING AND/OR SEQUENCING VECTOR	GABANT, PHILIPPE
09225152	6180407	150	01/04/1998	CLONING AND/ OR SEQUENCING VECTOR	GABANT , PHILIPPE
08379614	5910438	150	07/20/1995	CLONING AND/OR SEQUENCING VECTOR	GABANT , PHILIPPE

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name	First Name
GABANT	PHILIPPE

Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Monday
Date: 3/1/2004
Time: 16:13:36

Inventor Name Search Result

Your Search was:

Last Name = ROSCAM-SZPIRER
First Name = JOSLANE

Application#	Patent#	Status	Date Filed	Title	Inventor Name 1
60143269	Not Issued	159	07/12/1999	NON-HUMAN GENETICALLY MODIFIED MAMMAL LACKING THE ALPHA-FETOPROTEIN	ROSCAM-SZPIRER , JOSLANE

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name ROSCAM-SZPIRER **First Name** JOSLANE

Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page